Characterizing septum inhibition in Mycobacterium tuberculosis for novel drug discovery

被引:26
|
作者
Respicio, Laurel [2 ]
Nair, Pravin A. [1 ]
Huang, Qing [1 ]
Anil, Burcu [1 ]
Tracz, Sylvia [1 ]
Truglio, James J. [3 ]
Kisker, Caroline [4 ]
Raleigh, Daniel P. [1 ]
Ojima, Iwao [1 ]
Knudson, Dennis L. [5 ]
Tonge, Peter J. [1 ]
Slayden, Richard A. [2 ]
机构
[1] SUNY Stony Brook, Dept Chem, Inst Chem Biol & Drug Discovery, Stony Brook, NY 11794 USA
[2] Colorado State Univ, Dept Microbiol & Immunol Pathol, Mycobacteria Res Labs, Rocky Mt Reg Ctr Excellence, Ft Collins, CO 80523 USA
[3] SUNY Stony Brook, Struct Biol Ctr, Stony Brook, NY 11794 USA
[4] Univ Wurzburg, Inst Biol Struct, Rudolf Virchow Ctr Expt Biomed, D-97078 Wurzburg, Germany
[5] Colorado State Univ, Dept Bioagr Sci & Pest Management, Ft Collins, CO 80523 USA
关键词
Mycobacterium tuberculosis; cell division; FtsZ; septum inhibition; drug discovery;
D O I
10.1016/j.tube.2008.03.001
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A temperature sensitive mutation in the cell, division protein FtsZ was used in combination with transcriptional analysis to identify biomarkers for inhibition of septum formation. Crystallography and modeling revealed that the glycine for aspartate substitution at amino acid 210 was located in helix 8 of the protein, adjacent to the T7 synergy loop. To verify the molecular behavior of FtSZ(D210G), the in vitro activity and structural stability were evaluated as a function of temperature. These analyses confirmed that the FtsZ(D21OG) mutant had reduced GTPase and polymerization activity compared to wild-type FtsZ, and CD spectroscopy demonstrated that both FtsZD21OG and wild-type FtsZ had similar structure and stability. Significantly, the FtsZD21OG merodiploid strain of A tuberculosis had compromised growth at 37 degrees C, substantiating the suitability of FtSZ(D21OG) as a molecular toot for global analysis in response to improper FtsZ polymerization and septum inhibition. Advanced model-based bioinformatics and transcriptional mapping were used to identify high-content multiple features that provide biomarkers for the development of a rational drug screening platform for discovering novel chemotherapeutics that target cell division. (c) 2008 Published by Elsevier Ltd.
引用
收藏
页码:420 / 429
页数:10
相关论文
共 50 条
  • [21] Identification and validation of novel drug targets in Mycobacterium tuberculosis
    Singh, Vinayak
    Mizrahi, Valerie
    DRUG DISCOVERY TODAY, 2017, 22 (03) : 503 - 509
  • [22] Novel strategies for the detection of drug resistance in Mycobacterium tuberculosis
    Telenti, A
    Persing, DH
    RESEARCH IN MICROBIOLOGY, 1996, 147 (1-2) : 73 - 79
  • [23] Characterizing Mycobacterium tuberculosis isolates from Karachi, Pakistan: drug resistance and genotypes
    Ayaz, Afsheen
    Hasan, Zahra
    Jafri, Sana
    Inayat, Raunaq
    Mangi, Rafique
    Channa, Abid Ali
    Malik, Faisal Riaz
    Ali, Asho
    Rafiq, Yasraba
    Hasan, Rumina
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2012, 16 (04) : E303 - E309
  • [24] The cell-wall core of Mycobacterium tuberculosis in the context of drug discovery
    Brennan, Patrick J.
    Crick, Dean C.
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2007, 7 (05) : 475 - 488
  • [25] A multitarget approach to drug discovery inhibiting Mycobacterium tuberculosis PyrG and PanK
    Laurent R. Chiarelli
    Giorgia Mori
    Beatrice Silvia Orena
    Marta Esposito
    Thomas Lane
    Ana Luisa de Jesus Lopes Ribeiro
    Giulia Degiacomi
    Júlia Zemanová
    Sára Szádocka
    Stanislav Huszár
    Zuzana Palčeková
    Marcello Manfredi
    Fabio Gosetti
    Joël Lelièvre
    Lluis Ballell
    Elena Kazakova
    Vadim Makarov
    Emilio Marengo
    Katarina Mikusova
    Stewart T. Cole
    Giovanna Riccardi
    Sean Ekins
    Maria Rosalia Pasca
    Scientific Reports, 8
  • [26] Comparing and Validating Machine Learning Models for Mycobacterium tuberculosis Drug Discovery
    Lane, Thomas
    Russo, Daniel P.
    Zorn, Kimberley M.
    Clark, Alex M.
    Korotcov, Alexandru
    Tkachenko, Valery
    Reynolds, Robert C.
    Perryman, Alexander L.
    Freundlich, Joel S.
    Ekins, Sean
    MOLECULAR PHARMACEUTICS, 2018, 15 (10) : 4346 - 4360
  • [27] NMR for lead identification and optimization: Drug discovery targeting Mycobacterium tuberculosis
    Kapilashrami, Kanishk
    Machutta, Carl A.
    Bommineni, Gopal Reddy
    Picart, Francis
    Tonge, Peter
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 242
  • [28] Genetics-directed drug discovery for combating Mycobacterium tuberculosis infection
    Quan, Yuan
    Xiong, Le
    Chen, Jing
    Zhang, Hong-Yu
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2017, 35 (03): : 616 - 621
  • [29] A multitarget approach to drug discovery inhibiting Mycobacterium tuberculosis PyrG and PanK
    Chiarelli, Laurent R.
    Mori, Giorgia
    Orena, Beatrice Silvia
    Esposito, Marta
    Lane, Thomas
    de Jesus Lopes Ribeiro, Ana Luisa
    Degiacomi, Giulia
    Zemanova, Julia
    Szadocka, Sara
    Huszar, Stanislav
    Palcekova, Zuzana
    Manfredi, Marcello
    Gosetti, Fabio
    Lelievre, Joel
    Ballell, Lluis
    Kazakova, Elena
    Makarov, Vadim
    Marengo, Emilio
    Mikusova, Katarina
    Cole, Stewart T.
    Riccardi, Giovanna
    Ekins, Sean
    Pasca, Maria Rosalia
    SCIENTIFIC REPORTS, 2018, 8
  • [30] Comparing and validating machine learning models for Mycobacterium tuberculosis drug discovery
    Lane, Thomas
    Russo, Daniel
    Zorn, Kimberley
    Clark, Alex
    Korotcov, Alexandru
    Tkachenko, Valery
    Reynolds, Robert
    Perryman, Alexander
    Freundlich, Joel
    Ekins, Sean
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2018, 256